Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Spectrum Pharmaceuticals, Inc. - Common Stock (NQ:SPPI)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Spectrum Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stocks That Hit 52-Week Lows On Monday
  On Monday, 297 companies reached new 52-week lows. 
Via Benzinga
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPPI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
After FDA Rejection, Spectrum Shelves Development On Poziotinib
Via Benzinga
Expert Ratings for Spectrum Pharmaceuticals
Via Benzinga
SPPI EQUITY NOTICE: Rosen Law Firm Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPI
From The Rosen Law Firm, P.A.
Via Business Wire
Spectrum Pharmaceuticals, Inc. (SPPI) Shareholder Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Spectrum Pharmaceuticals, Inc.
From Robbins LLP
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Spectrum Pharmaceuticals, Inc. (SPPI)
From Robbins LLP
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Class Action on Behalf of Investors in Spectrum Pharmaceuticals, Inc. and Advises Shareholders with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Spectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff
From Spectrum Pharmaceuticals
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Spectrum, F45 Training, PROG, and Fox and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. 
Via Benzinga
Marathon Oil To Rally Around 65%? Plus This Analyst Cuts PT On Twilio By 55%
Raymond James raised the price target on Marathon Oil Corporation (NYSE: MRO) from $37 to $48. Raymond James analyst John Freeman maintained a Strong Buy rating on the stock. Marathon Oil shares fell... 
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, Cantaloupe, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Lufax Holding Shares Are Trading Lower By Over 11%; Here Are 21 Stocks Moving Premarket
Gainers VEON Ltd. (NASDAQ: VEON) shares rose 31.1% to $0.6095 in pre-market trading after the company agreed to sell its Russian business, Vimpelcom for 130 billion roubles ($2.2 billion). 
Via Benzinga
Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, Cantaloupe, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022
Upgrades 
Via Benzinga
Spectrum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, EyePoint, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Earnings Scheduled For November 10, 2022
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter. 
Via Benzinga
Spectrum Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
EQUITY ALERT: Rosen Law Firm Encourages Spectrum Pharmaceuticals, Inc. Investors to Inquire About Class Action Investigation – SPPI
From Rosen Law Firm
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Spectrum, F45 Training, PROG, and UiPath and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™ (eflapegrastim-xnst) Injection
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, F45, and PROG and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, and F45 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.